646 results about "Gastrointestines" patented technology

The invention discloses a probiotic-polyphenol nanoparticle colon-targeted co-delivery system as well as a preparation method and application thereof, and belongs to the field of biological medicines. The FCPs and hyaluronic acid (HA) are combined through non-covalent interaction, so that the hydrogel has colon targeting property and mucosal adhesion at the same time, and delivery of probiotics is facilitated. The hydrogel (HF) based on polysaccharide has good biocompatibility, and can be used for effectively encapsulating the probiotics and the natural products. Then, the PDA-TH NPs and BA are incorporated into the polysaccharide chain network of HF, and finally the BA-HF-PDAT targeted co-delivery system is constructed. The BA (at) HF-PDAT targeted co-delivery system can protect BA from serious gastrointestinal stress, and is jointly assembled with PDT-TH NPs to realize dual slow release of thymol (Thy), so that the treatment effect of BA and Thy is improved, and the BA (at) HF-PDAT targeted co-delivery system contributes to treatment of clostridium difficile infection (CDI).

S-Beta-hydroxybutyric acid compositions for oral delivery are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and / or as a gel or suspension. By limiting added beta-hydroxybutyrate salts containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be pure S-beta-hydroxybutyric acid or a non-racemic mixture enriched with S-beta-hydroxybutyric acid relative to R-beta-hydroxybutyric acid.

The invention relates to a feeding intolerance burst risk early warning method and device based on multi-modal dynamic monitoring. The method comprises the steps that a gastrointestinal tract peristaltic wave image sequence under the abdominal skin surface of a patient is collected; collecting borborygmus data; collecting physical sign physiological data of the patient; monitoring behavior and posture data of the patient in real time; tracking the infinitesimal displacement and deformation of the gastrointestinal wall in the gastrointestinal tract peristaltic wave image sequence, and extracting and quantifying the speed, direction and wave crest and trough change rate of the peristaltic wave and the regularity index of the peristaltic wave; calculating a physiological deviation degree between the fusion feature at the current moment and an expected normal mode generated by the physiological feature baseline model of the patient; and inputting the physiological deviation degree, the change rate of the physiological deviation degree in the time dimension and the accumulated deviation duration into a conditional variation risk assessment model, and outputting a potential spatial distance. Through the non-invasive and highly quantified feeding intolerance risk model, the early recognition capability and clinical intervention efficiency of feeding intolerance are remarkably improved.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

The invention belongs to the technical field of biological medicines, and discloses a traditional Chinese medicine composition for treating microsatellite stability (MSS) type tumors by a sensitization immune checkpoint inhibitor. The traditional Chinese medicine composition provided by the invention comprises radix scutellariae, rhizoma zingiberis, Chinese herbaceous peony, liquorice root and Chinese date, can increase CD8 + T cell infiltration, promote the CD8 + T cell to secrete cytokines and improve the immunosuppression of MSS type tumors, and further breaks through the conventional range of anti-tumor treatment of immune examination inhibitors; meanwhile, the traditional Chinese medicine composition can also improve adverse reaction of gastrointestinal tracts caused by tumor treatment by an immune examination inhibitor, and the life quality of patients is improved.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The invention discloses lactobacillus mucus YF28 and application thereof, and belongs to the technical field of microorganisms. The fermented lactobacillus mucus YF28 is separated from Hu sheep manure, is classified and named as the fermented lactobacillus mucus YF28, and has the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 20252433. The fermented lactobacillus mucilaginosus YF28 has good tolerance in the gastrointestinal environment and can reach the intestinal tract to play a role. The bacterial strain has strong intestinal adhesion capacity, is easy to form a probiotic biological membrane, and is beneficial to intestinal health. The fermented lactobacillus mucus YF28 can promote peristalsis, enrich the abundance of Akkermansia bacteria and bacteriophage thereof, restore the water content of excrement to a normal level, and significantly promote intestinal health. The invention has an application prospect in the development of drugs or health-care foods with the function of relieving constipation and related gastrointestinal symptoms.

The invention relates to the technical field of pharmaceutical preparations, and provides an oral solid preparation for treating gout and a preparation method thereof. The preparation method comprises the following steps: sieving a filling agent, a disintegrating agent, an adhesive and dotenorad to obtain a sieved material; and mixing the sieved material and a lubricant, and tabletting to obtain the oral solid preparation for treating gout, the filling agent is lactose, mannitol and microcrystalline cellulose. By optimizing the prescription and the preparation process, the dissolution rate and bioavailability of the medicine are improved, so that the curative effect is improved; by selecting proper auxiliary materials and preparation types, the stimulation to gastrointestinal tracts is reduced, and the tolerance of patients is improved; the oral solid preparation is convenient to take, accurate in dosage, high in patient compliance and beneficial to long-term treatment; moreover, the preparation method provided by the invention is simple to operate, easy for industrial production and relatively low in cost.

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

The invention belongs to the technical field of medical image processing, and provides a multi-modal medical image analysis system, medium and equipment for gastrointestinal disease recognition, and the technical scheme is as follows: extracting multi-scale texture features and structural features of a gastrointestinal endoscopy color image and a gastrointestinal endoscopy OCT depth image respectively, and fusing to obtain a cross-modal feature sequence; based on the feature sequence added with the position code, learning a spatial corresponding relation of different modal data on blood vessel morphology and gastrointestinal tract wall interlayer structure; obtaining a multi-scale global context feature sequence and a local detail feature sequence based on the aligned cross-modal blood vessel and gastrointestinal tract wall interlayer structure features, and fusing the multi-scale global context feature sequence and the local detail feature sequence to obtain fused multi-modal features; obtaining an adjusted dense deformation field based on the fused multi-modal features; and performing coarse registration and fine registration based on the adjusted dense deformation field to obtain a registered gastrointestinal endoscopy color image and a registered gastrointestinal endoscopy OCT depth image. The anti-interference capability is strong, and the data stability is high.

The present invention is directed to novel compounds that inhibit Nav1.8 sodium channels, methods of making, and methods of using thereof. The present disclosure is further directed to administering the disclosed compounds as therapeutic solutions for chronic pain, primary pain, idiopathic pain, gastrointestinal pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer-related pain, idiopathic pain, postoperative pain, visceral pain, multiple sclerosis, Summer-Marr-Tuff syndrome, incontinence, pathological cough, or arrhythmia to a subject in need thereof.

Systems and methods for anchoring and restraining gastrointestinal prostheses are disclosed. In various examples, the systems and methods include securing a gastrointestinal device within a patient's anatomy by extending an anti-migration anchor through a plurality of portions of the gastrointestinal device to couple together the plurality of portions of the gastrointestinal device. In some examples, the anti-migration anchor extends through tissue situated between the plurality of portions of the gastrointestinal device.

The invention belongs to the technical field of medical treatment, and discloses an osteoarthritis rehabilitation auxiliary device and system, and the device comprises an intelligent vibration treatment module, a pressure sensor and biological feedback module, an intelligent control and APP remote management module, a pressure sensor, an accelerometer, and a myoelectricity sensor. The joint pain is relieved, vibration can stimulate sensory nerves, pain signal transmission is reduced, and the pain degree is reduced. Vibration promotes secretion of joint fluid, friction is reduced, and the range of motion is improved. Low-frequency vibration stimulates the activity of cartilage cells, and cartilage degeneration is slowed down. And a biological feedback system is intelligently regulated and controlled, so that the treatment accuracy is improved. Non-invasive treatment is achieved, and no side effect exists; gastrointestinal discomfort caused by drug treatment or high cost of long-term physical treatment is avoided. Remote monitoring is achieved, compliance is improved, a patient can be treated at home and does not need to see a doctor frequently, and medical cost is reduced.

The present invention belongs to the field of biotechnology and pharmaceutical engineering technology, and discloses a functionalized drug-loaded exosome based on milk exosomes, a preparation method thereof, and an application thereof. The functionalized drug-loaded exosomes include a carrier and a water-insoluble drug, and the water-insoluble drug is loaded inside the carrier; wherein the surface of the carrier is loaded with milk exosomes with functionalized molecules, and the functionalized molecule is any one of phosphatidylserine, a molecule capable of macrophage targeting, and a molecule or polymer that enhances the targeting and stability of milk exosomes; the water-insoluble drug is any one of an antibacterial drug, an antitumor drug, and a gene drug. The functionalized drug-loaded exosomes in the present invention can improve the gastrointestinal stability of oral administration and enhance the efficacy against bacterial pathogens; expand the application scope of milk exosomes in the fields of anti-intestinal bacterial infection and food preservation, and the exosome content in milk is very rich, which is convenient for large-scale preparation and has important application value.

Provided herein are variant α4β7 integrin antibodies and methods of use.

The inhalation suspension preparation containing the SGC receptor stimulant comprises the SGC receptor stimulant with an effective therapeutic dose or pharmaceutically acceptable salt of the SGC receptor stimulant, and pharmaceutically acceptable auxiliary materials of the suspension preparation, the pharmaceutically acceptable auxiliary materials of the suspension preparation comprise at least one of a surfactant, a pH regulator, an osmotic pressure regulator and a metal complexing agent; the inhalation suspension preparation containing the riociguat shows good lung absorption efficiency, is beneficial to reaching the same or better treatment level by reducing the administration dosage, can directly act on a diseased region through an administration route, takes effect more quickly compared with oral administration of the riociguat, and has a good application prospect. Gastrointestinal discomfort and systemic hypotension side effects caused by gastrointestinal tract contact and absorption entering a circulatory system can be avoided, the treatment cycle of an oral dosage form dosage titration administration scheme is shortened, and a better treatment scheme is provided for relieving dyspnea and syncope symptoms of pulmonary hypertension patients treated at home.

The invention discloses a magnetic control soft robot with electrical stimulation and drug release functions, and relates to the technical field of medical instruments. In the magnetic control soft robot provided by the invention, the magnetic layer is used for driving the body to move and position in the gastrointestinal tract under the driving of an external magnetic field; the electric control layer is used for supplying power and is responsible for controlling the opportunity and parameters of electric stimulation and controlling a drug release instruction; after a microneedle of the conductive hydrogel microneedle layer penetrates into tissue, nerve endings or muscle cells can be stimulated by applying a weak electric signal so as to regulate gastrointestinal motility, relieve pain and the like, a drug can be loaded in the microneedle, and when the electric signal is applied, the drug can be loaded in the microneedle by means of electromigration, electroosmosis and the like. Triggering the drug to be controllably released into the target tissue as required; the adhesive layer is used for temporarily anchoring the robot at a specific working position of the gastrointestinal tract; according to the magnetic control soft robot and the preparation method thereof, the comprehensive requirements of gastrointestinal tract disease treatment can be met.

The invention relates to the technical field of oral non-biological medicine preparations, in particular to an upatinib sustained release tablet and a preparation method thereof. The invention discloses a preparation method of an upatinib sustained-release tablet, and aims to solve the problem that the dissolution rate of the upatinib sustained-release tablet is unstable, namely, the upatinib sustained-release tablet can stably control the release of upatinib in different gastrointestinal tract environments through the synergistic cooperation of all the components of the upatinib sustained-release tablet, and the preparation method of the upatinib sustained-release tablet is relatively low in cost and easy to operate. The large-scale production is facilitated; the upatinib sustained release tablet comprises the following components in percentage by weight: 3.0%-3.5% of upatinib, 18%-19.50% of a pH regulator, 50%-55% of a filler, 17%-22% of an adhesive, 0.1%-1% of a flow aid, 1%-2% of a lubricant and 0.01%-10.9% of a coating material.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

The invention provides a loxoprofen sodium double-release capsule micro-tablet and a preparation method of the loxoprofen sodium double-release capsule micro-tablet. Through the synergistic effect of the quick-release micro-tablet and the sustained-release micro-tablet, the quick-release micro-tablet can realize quick release and absorption, and the sustained-release micro-tablet can maintain relatively stable blood concentration for a long time. The administration frequency is reduced, the coordination of the postprandial administration requirement and the dietary habit is ensured, and the occurrence of gastrointestinal tract adverse reactions is reduced. The preparation provided by the invention conforms to the dosage form design of the hour pharmacology, can quickly take effect through administration twice every day, can maintain the blood concentration in the high-incidence time period of night diseases, avoids the disadvantage of taking medicine after meal when the night diseases attack, guarantees the sleep quality, and improves the overall treatment effect. The micro tablet is small in size and easy to swallow, and the medication compliance of patients with dysphagia is obviously improved. Through dosage form design and improvement, unmet clinical requirements are expected to be met by virtue of obvious advantages of the traditional Chinese medicine composition.

The invention provides lactobacillus gasseri JY01, and belongs to the technical field of probiotic application, the lactobacillus gasseri JY01 is preserved in Guangdong Microbial Culture Collection Center on May 21, 2025, the preservation number is GDMCC NO. 66341, and the nucleotide sequence is shown as SEQ ID No: 1. The strain is obtained by separating and purifying a pickle sample produced in Liaoning region of China, has multiple functions of producing gamma-aminobutyric acid (GABA) at high yield, reducing blood sugar, resisting oxidation, regulating gastrointestinal tracts and the like, and has very high application value and economic value.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA in a cell or subject, and in certain instances reducing the amount of SCN2A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a disease or disorder associated with a voltage-gated sodium channel protein, such as, for example, a Developmental and Epileptic Encephalopathy, an intellectual disability, or an autism spectrum disorder. Such symptoms and hallmarks include, but are not limited to seizures, hypotonia, sensory integration disorders, motor development delays and dysfunctions, intellectual and cognitive dysfunctions, movement and balance dysfunctions, visual dysfunctions, delayed language and speech, gastrointestinal disorders, neurodevelopmental delays, sleep problems, and sudden unexpected death in epilepsy.

The use of 2'-fucosyllactose in the preparation of a food / drug for promoting intestinal glycocalyx development and preventing intestinal glycocalyx damage caused by lipopolysaccharide (LPS). The use of 2'-fucosyllactose in the preparation of a food / drug for the adjuvant treatment and / or adjuvant prevention of gastrointestinal infections, inflammatory bowel diseases, obesity or allergy caused by glycocalyx damage. Before adherent growth of Caco-2 cells, adding 2'-FL for co-culture with the Caco-2 cells can simulate the intestinal growth and maturation state. In the state, 2'-FL can significantly promote the development of the glycocalyx layer of Caco-2 cells, and can further prevent the glycocalyx layer damage caused by LPS on this basis.

The invention discloses application of low-esterification pectin in preparation of intelligent nanoparticles for oral delivery of insulin. The application comprises preparation of pectin with different esterification degrees, subcritical water treatment of pectin and preparation of pectin-based intelligent nanoparticles. According to the invention, through esterification degree regulation and control of pectin, a subcritical water treatment process and use of appropriate auxiliary materials, the embedding efficiency of insulin and the stability of nanoparticles are remarkably improved, the degradation of insulin in a gastrointestinal tract environment is reduced, and the oral bioavailability of drugs is improved.

The invention relates to the field of medical apparatus and instruments, in particular to a gastrointestinal flora sampling device which comprises a collecting assembly, the collecting assembly is used for collecting excrement of a patient, the collecting assembly is communicated with a classifying assembly, the classifying assembly is used for equally dividing and transporting the excrement, and the classifying assembly is further used for self-cleaning in the excrement transportation process. The output end of the classification assembly communicates with a sampling assembly and a processing assembly, the sampling assembly is used for storing excrement for gastrointestinal flora examination, and the processing assembly is used for processing excrement which is not used for gastrointestinal flora examination; the system further comprises a control system, the control system is used for judging whether each group of excrement in the classification assembly can be used for gastrointestinal flora examination or not, when the excrement can be used for gastrointestinal flora examination, the classification assembly and the sampling assembly are controlled to work to sample the excrement, and when the excrement cannot be used for gastrointestinal flora examination, the sampling assembly is controlled to sample the excrement. And the classification assembly and the treatment assembly are controlled to treat the excrement. The excrement sampling device is used for reducing the excrement sampling difficulty.

The present invention relates to a system for monitoring gastrointestinal disorders, the system including a gastrointestinal probe, at least one sensor configured to measure a patient parameter, a patient interface configured to receive input from the patient, and a processor configured to: determine a first value and a second value corresponding to a given time interval, where if the input from the patient corresponds to the given time interval, the first value is determined based on a measurement of the parameter corresponding to the given time interval and based on the input from the patient corresponding to the given time interval, and the second value is determined based on a measurement of gastroesophageal contents corresponding to the given time interval; and determine a level of gastrointestinal disorders based on the set of determined value pairs.